AstraZeneca's Lynparza delays progression risk in prostate cancer

Pharmaceutical company AstraZeneca said on Tuesday that results from a recent study revealed that its Lynparza asset reduced the risk of first-line metastatic castration-resistant prostate cancer progression by 34% when used in combination with abiraterone.

AstraZeneca

10,292.00p

16:49 14/11/24

1.46%

148.00p

FTSE 100

8,071.19

16:49 14/11/24

n/a

FTSE 350

4,459.02

16:38 14/11/24

n/a

FTSE All-Share

4,417.25

16:54 14/11/24

n/a

Pharmaceuticals & Biotechnology

19,794.96

16:38 14/11/24

0.96%

187.95

AstraZeneca stated the combination demonstrated "a statistically significant and clinically meaningful improvement" in radiographic progression-free survival versus current standard-of-care.

Susan Galbraith, AZN's executive vice president of Oncology R&D, said: "This Lynparza combination has the potential to afford first-line patients more time without disease progression while also maintaining their quality of life.

"The PROpel results are impressive because active comparator trials set a high bar and, in this trial, Lynparza plus abiraterone showed a significant clinical improvement when compared to an active standard of care in patients with metastatic castration-resistant prostate cancer, regardless of whether they have an HRR gene mutation."